Tris trial is registered with FDA with number: NCT01323192. The sponsor of the trial is Janssen Pharmaceutical K.K. and it is looking for 284 volunteers for the current phase.
Official trial title:
A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day